- Sumitomo Pharma (Boston, MA)
- …of early- to late-stage investigational assets, we aim to accelerate discovery, research , and development to bring novel therapies to patients sooner. For more ... IT systems supporting GxP processes comply with FDA 21 CFR Part 11, EU Annex 11, and other applicable...to late-stage investigational assets, we aim to accelerate discovery, research , and development to bring novel therapies to patients… more